Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.28%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Mainz Biomed NV [MYNZ]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Buy; Adjusting PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Partnership Inked For U.S. Go-To-Market Strategy; Reiterate Buy; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
U.S. Biomarker Study Reports Positive Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Novel Biomarkers Generate Robust Data; Reiterate Buy; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Buy; Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Commercial Partnership Inked in Poland; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Commercialization in Spain and Portugal Expanded; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
mRNA Biomarkers Show Positive Results in Feasibility Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Commercial Footprint Expanded in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
U.S. Extension of ColoFuture Study Enrolls First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
U.S. Pivotal Study of ColoAlert Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
U.S. Extension of ColoFuture Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
ColoAlert Commercially Launched in Italy and UAE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
First Patient Enrolled For Integration of mRNA Biomarkers Into ColoAlert
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Mainz Biomed NV
Industry: Medical - Biomedical and Genetics
Non-Invasive Colorectal Cancer Screening From Europe; Initiating at Buy and $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
|